PMSF

Cat. No.:	HY-B0496		
CAS No.:	329-98-6		
Molecular Formula:	C ₇ H ₇ FO ₂ S		
Molecular Weight:	174.19		
Target:	Cathepsin		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

SOLVENT & SOLUBILITY

Isopropanol : 60 H ₂ O : < 0.1 mg/m Preparing	Isopropanol : 60 mg/r	DMSO : 250 mg/mL (1435.21 mM; Need ultrasonic) Isopropanol : 60 mg/mL (344.45 mM; Need ultrasonic) H ₂ O : < 0.1 mg/mL (insoluble)						
		Solvent Mass Concentration	1 mg	5 mg	10 mg			
	Preparing Stock Solutions	1 mM	5.7409 mL	28.7043 mL	57.4086 mL			
		5 mM	1.1482 mL	5.7409 mL	11.4817 mL			
		10 mM	0.5741 mL	2.8704 mL	5.7409 mL			
	Please refer to the so	Please refer to the solubility information to select the appropriate solvent.						
In Vivo		1. Add each solvent one by one: corn oil Solubility: 20 mg/mL (114.82 mM); Clear solution; Need ultrasonic						
		 Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2 mg/mL (11.48 mM); Clear solution 						
		 Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2 mg/mL (11.48 mM); Clear solution 						
		 Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2 mg/mL (11.48 mM); Clear solution 						

Product Data Sheet

0,′¢

F



	inhibition of phosphoinositide turnover is due to one or more steps following phosphoinositide breakdown ^[1] . PMSF inhibits the acylation of the inositol residue of GPI intermediates in bloodstream-form T. brucei. PMSF inhibits the formation of glycolipid C but does not inhibit fatty acid remodeling in vitro. PMSF inhibits GPI acylation and ethanolamine phosphate addition in procyclic trypanosomes but not in Hela cells ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	PMSF (0.1 mL/10 g b.wt, i.p.) produces antinociception as indicated by the dose-responsive increase in % MPE in the tail-flick latency evaluation, but fails to produce a clear dose-responsive inhibition of locomotion. Mice receiving i.p. injections of PMSF exhibit cannabinoid effects that includes antinociception, hypothermia and immobility with ED ₅₀ values of 86, 224 and 206 mg/kg, respectively. PMSF (30 mg/kg) pretreatment potentiates the effects of anandamide on tail-flick response (antinociception), spontaneous activity and mobility by 5-, 10- and 8-fold, respectively ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[3] Male ICR mice weighing 18 to 25 g are used in the assay. PMSF is dissolved in sesame oil and administered i.p. at a volume of 0.1 mL/10 g b.wt. PMSF is always administered 10 min before i.v. anandamide or vehicle injections. Mice are acclimated to the evaluation room overnight without interruption of food or water. After i.v. anandamide or vehicle administration each animal is evaluated as follows: tail-flick latency (antinociception) response at 5 min and spontaneous (locomotor) activity at 5 to 15 min; or core (rectal) temperature at 5 min and ring-immobility (catalepsy) at 5 to 10 min. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Circulation. 2022 Mar;145(9):675-687.
- Autophagy. 2022 Nov 30.
- Autophagy. 2020 Dec 6.
- Small. 2020 Dec 2;e2004879.
- EMBO Mol Med. 2023 Aug 8;e16836.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Sekar, M.C. and B.D. Roufogalis, Differential effects of phenylmethanesulfonyl fluoride (PMSF) on carbachol and potassium stimulated phosphoinositide turnover and contraction in longitudinal smooth muscle of guinea pig ileum. Cell Calcium, 1984. 5(3): p.

[2]. Guther, M.L., W.J. Masterson, and M.A. Ferguson, The effects of phenylmethylsulfonyl fluoride on inositol-acylation and fatty acid remodeling in African trypanosomes. J Biol Chem, 1994. 269(28): p. 18694-701.

[3]. Compton, D.R. and B.R. Martin, The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther, 1997. 283(3): p. 1138-43.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA